Stock listing

OTC:VRPX Virpax Pharmaceuticals, Inc. Stock

Follow Virpax Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · OTC:VRPX

$0.0020 USD 0.0000 (0.0%)

Close on Nov 12, 2026

Past year +900.0% · daily closes, Oct 8, 2026 – Nov 12, 2026, adjusted for splits
Day range
$0.0020 – $0.0020 USDNov 12, 2026
Market cap
$2,485 USDAt the close on Nov 12, 2026 · price × 1.24M shares outstanding
Traded on an average day
$0 USDMedian day 0 shares · 17 days with no trades · last 3 months, Oct 8, 2026 – Nov 12, 2026
Virpax Pharmaceuticals, Inc. logo

Daily closes

Last 3 months, Oct 8, 2026 – Nov 12, 2026 · OTC:VRPX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.0020+0.0004+25.0%$0.0020$0.0020$0.0020356
$0.0016+0.0006+60.0%$0.0016$0.0016$0.0016303
$0.0010-0.0010-50.0%$0.0010$0.0010$0.0010212
$0.00200.00000.0%$0.0020$0.0020$0.00200
$0.0020+0.0017+566.7%$0.0020$0.0020$0.0020800
$0.00030.00000.0%$0.0003$0.0003$0.00030
$0.00030.00000.0%$0.0003$0.0003$0.0003687
$0.0003-0.0005-62.5%$0.0003$0.0003$0.0003113
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00085,127
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.00080.00000.0%$0.0008$0.0008$0.00080
$0.0008+0.0006+300.0%$0.0008$0.0008$0.0008287
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.0002——$0.0002$0.0306$0.0002802

Splits

2 splits since 2024 · OTC:VRPX · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-10Consolidation
Ticker
OTC:VRPX
Asset type
Stock
Exchange
OTC
Currency
USD

Virpax Pharmaceuticals, Inc. on 6ix

Decks
2 decks · latest Sep 10, 2021

Valuation

price Nov 12, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
1.26

Events

QuarterResults
Q4 2024Mar 3, 2025 · After close
Q3 2024Nov 14, 2024 · After close
Q2 2024Aug 12, 2024 · After close
Q1 2024May 13, 2024 · After close
Q4 2023Mar 26, 2024 · Before open
Q3 2023Nov 15, 2023 · After close
Q2 2023Aug 14, 2023 · Before open
Q1 2023May 12, 2023 · After close
Q4 2022Mar 22, 2023 · Before open
Q3 2022Nov 9, 2022 · After close
All 17 quarters
QuarterResults
Q2 2022Aug 15, 2022 · After close
Q1 2022May 16, 2022 · After close
Q4 2021Mar 31, 2022 · After close
Q3 2021Dec 1, 2021
Q2 2021Aug 10, 2021
Q1 2021May 17, 2021
Q4 2020Mar 31, 2021

Open Events

Decks

DeckKindSlidesDate
IPO Roadshow (September 2021)IPO roadshow31 slidesSep 10, 2021
IPO Roadshow (January 2021)IPO roadshow29 slidesJan 8, 2021

Open Decks

Financials

Annual, in USD

Income statement

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000000
Research and development5.82M5.12M10.8M4.84M1.29M622.7K1.14M
Selling, general and administrative6.26M7.82M11.1M7.19M2.90M2.56M1.48M
Operating income-12.1M-12.9M-21.8M-12.0M-4.20M-3.18M-2.63M
Depreciation and amortization12.9M12.9M18.3M12.0M4.20M3.18M2.63M
EBITDA859.9K0-3.50M0000
Interest expense103.8K194.4K92.8K147.9K124.6K15.0K
Income before tax-12.1M-15.2M-21.7M-12.1M-4.34M-3.31M-2.64M
Income tax-12.9K-194.4K92.8K147.9K124.6K-161.1K
Net income-12.1M-15.2M-21.5M-12.1M-4.49M-3.43M-2.64M
Earnings per share, basic-2.84-12.97-18.32-10.37-9.07-6.58-0.53

Balance sheet

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents1.51M9.14M19.0M36.8M54.8K41.5K48.4K
Short-term investments1.51B
Receivables01.39K0
Inventory3.33K
Current assets1.56M9.63M19.7M39.6M73.1K46.7K61.5K
Total assets1.56M9.63M19.7M39.6M465.4K46.7K61.5K
Accounts payable18.5K1837.6K19.8K22.1K3.50K6.55K
Current liabilities2.47M7.69M3.09M2.09M3.66M2.78M1.25M
Long-term debt1.02M
Total debt1.57M1.26M500.0K
Total liabilities2.47M7.69M3.09M2.09M4.68M2.78M1.25M
Shareholders' equity-913.8K1.93M16.6M37.5M-4.22M-2.73M-1.19M
Shares outstanding4.25M1.17M1.17M1.17M494.5K521.5K4.95M

Cash flow

LineFY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-16.7B-9.85M-17.8M-14.5M-1.38M-1.13M-1.80M
Capital spending0000000
Free cash flow-16.7B-9.85M-17.8M-14.5M-1.38M-1.13M-1.80M
Cash from financing9.08B050.9K51.3M1.40M1.13M1.67M
Change in cash-7.63B-9.85M-17.8M36.8M13.3K-6.83K-124.9K

Open Financials

Cap table

Built by 6ix from Virpax Pharmaceuticals, Inc.’s releases

Common shares
1,242,504
Fully diluted
1,242,504

Fully diluted

LineShares
Common shares1,242,504

Share count over time

CountShares
Nov 22, 20261,242,504

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary Jacob
Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Cardiff Oncology, Inc. (Director · Jan 23, 2012 – Mar 23, 2021 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past)
Director · Feb 16, 2021 – Jan 1, 2022 · Past
Katharyn Field
Other companies: Advasa Holdings, Inc. (Chief Financial Officer · Since at least Aug 11, 2026); BioRestorative Therapies, Inc. (Chief Executive Officer of iSpecimen Inc. (Nasdaq: ISPC) · Since at least Jun 10, 2026); LogProstyle Inc. (Director and Executive Officer, Director · Since at least Mar 18, 2026); Nuwellis, Inc. (Director · Since at least Jan 21, 2026); iSpecimen Inc. (Board Member · Since at least Sep 25, 2024)
Director · Jul 5, 2024 – Jul 5, 2024 · Past
Gary L Herman
Other companies: Trxade Group Inc (Director · Since at least Feb 4, 2026); Tron Inc. (Director · Since at least Aug 14, 2023); LQR House Inc. (Director · Aug 9, 2023 – Aug 9, 2023 · Past); DriveItAway Holdings Inc. (Director · Jul 6, 2017 – Jul 6, 2017 · Past)
Director · Jul 5, 2024 – Jul 5, 2024 · Past
Vinay Shah
Other companies: Azora Therapeutics, Inc. (Chief Financial Officer · Since at least Nov 16, 2024); Adial Pharmaceuticals, Inc (Chief Financial Officer · Since at least Nov 5, 2024); Aravive Inc (Chief Financial Officer · Oct 12, 2018 – Jan 24, 2022 · Past)
Chief Financial Officer · Jun 20, 2023 – Jan 29, 2024 · Past
Jatinder Dhaliwal
Other companies: BioRestorative Therapies, Inc. (Director · Since at least Jun 10, 2026); LQR House Inc. (Director · Aug 21, 2023 – Oct 14, 2024 · Past)
Director · Jul 5, 2024 – Jul 5, 2024 · Past
Vanila Singh
Other companies: NMP Acquisition Corp. (Director · Since at least Jun 30, 2025); BioDelivery Sciences International Inc (Director · Nov 22, 2019 – Mar 22, 2022 · Past)
Director · Feb 16, 2021 – Jan 29, 2024 · Past
Esha Randhawa
Other companies: BioRestorative Therapies, Inc. (Director · Since at least Jul 13, 2026)
Director · Nov 19, 2024 – Nov 19, 2024 · Past
Gerald W Bruce
Other companies: Nitromed Inc (Senior Vice President · Apr 27, 2006 – Mar 15, 2008 · Past)
Chief Executive Officer, Director · Feb 16, 2021 – Jan 29, 2024 · Past
Anthony P MackChief Executive Officer, Director · Feb 16, 2021 – Jan 25, 2023 · Past
Barbara RuskinDirector · Mar 24, 2023 – Jan 29, 2024 · Past
All 20 people
PersonSeat
Christopher Michael ChipmanChief Financial Officer · Feb 16, 2021 – Jan 25, 2023 · Past
Eric FloydDirector · Feb 16, 2021 – Jan 29, 2024 · Past
Jaydriane PanisDirector · Dec 17, 2024 – Dec 17, 2024 · Past
Jeffrey GudinChief Medical Officer, Director · Feb 16, 2021 – Jan 25, 2023 · Past
Jerrold SendrowDirector · Feb 16, 2021 – Jan 29, 2024 · Past
Judy SuDirector · Jul 5, 2024 – Jul 5, 2024 · Past
Michael F DubinDirector · Jul 26, 2021 – Jan 29, 2024 · Past
Sheila MathiasChief Scientific Officer · Sep 27, 2023 – Jan 29, 2024 · Past
Thani JambulingamDirector · Feb 16, 2021 – Jan 29, 2024 · Past
Usama ChaudhryChief Financial Officer · Nov 18, 2024 – Nov 18, 2024 · Past

Open People

Log in to ask 6ix AI your own questions about Virpax Pharmaceuticals, Inc.